All In Biotech

Drug Trial Radar · NCT05108870

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Actual

Start

Aug 22, 2022

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Lead sponsor
University of ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years. HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.

Conditions

  • Human Papilloma Virus
  • HPV
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • Head and Neck Cancer

Interventions

  • HB-201Drug

    A anti-cancer vaccine that treats HPV-related cancers.

  • HB-202Drug

    A anti-cancer vaccine that treats HPV-related cancers.

  • CarboplatinDrug

    Chemotherapy drug.

  • PaclitaxelDrug

    Chemotherapy drug.

  • Transoral Robotic SurgeryProcedure

    Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Primary Outcome: Phase 1 Dose of HB-201 and HB-201/202 Combined with ChemotherapyTime frame: 2 years
  2. Phase 2 Primary Outcome: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with ChemotherapyTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.